Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
Active, not recruiting · NCT06175390 · Registry updated 2026-02-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-02-06 | NCT06175390 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoffmann-La Roche | 280 |
| Institut Curie | 48 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institut Curie | Paris | France | 1 |
| Institut Curie | Saint-Cloud | France | 19 |